Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Soverini
Simona
S
Institute of Haematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. simona.soverini@tin.it
Martinelli
Giovanni
G
Colarossi
Sabrina
S
Gnani
Alessandra
A
Rondoni
Michela
M
Castagnetti
Fausto
F
Paolini
Stefania
S
Rosti
Gianantonio
G
Baccarani
Michele
M
D000293:Adolescent; D000368:Aged; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib